We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cancer Cells with p53 Mutations Have Phosphatidylinositol Signaling Molecules with Shortened Lipid Acyl Chains

By LabMedica International staff writers
Posted on 14 Jan 2015
A recent study showed that cancer cells with mutations in the p53 gene were distinguished by reduced-length fatty acid moieties in their cell membranes.

Phosphatidylinositol phosphate (PIP) second messengers relay growth cues via the cell membrane through the phosphorylation status of the inositol sugar, a signal transduction system that is deregulated in cancer. In contrast to PIP inositol head-group phosphorylation, changes in phosphatidylinositol (PI) lipid acyl chains in cancer have remained ill-defined.

Image: Molecular structure of phosphatidylinositol (Photo courtesy of Wikimedia Commons).
Image: Molecular structure of phosphatidylinositol (Photo courtesy of Wikimedia Commons).

Investigators at Cold Spring Harbor Laboratory (NY, USA) applied a mass-spectrometry-based method capable of unbiased high-throughput identification to quantify cellular PI acyl chain composition. Using this approach, they found that PI lipid chains represented a cell-specific fingerprint that was unperturbed by serum-mediated signaling in contrast to the inositol head group. Mutation of p53 resulted in PIs containing fatty acid moieties reduced in length by from two to four carbon atoms.

"What we would like to find out now," said senior author Dr. Lloyd Trotman, an associate professor at Cold Spring Harbor Laboratory, "is whether the p53-induced changes in the PI molecule are important in either making or maintaining the cancer state. If so, then in addition to p53 mutations, there may be other ways for cancer cells to generate the same or related changes. We will be looking for this in tissue samples from cancer patients."

The study was published in the December 24, 2014, online edition of the journal Cell Reports.

Related Links:

Cold Spring Harbor Laboratory



Gold Member
Turnkey Packaging Solution
HLX
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries